CD19 and acute lymphoblastic leukemia: Patient 1 with B-ALL, showed recurrence after 2 hematopoietic stem cell transplantations and achieved CR after treatment with the anti-CD19 CAR protocol, and durable CR was achieved after 24 months (Figure 4B).